Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 1, 2010, Pages 53-61

  Avila Gomez, Isabel Cristina ^a   Velez Pardo, Carlos ^a   Jimenez Del Rio, Marlene ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM PYRROLIDINEDITHIOCARBAMATE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIFITHRIN ALPHA; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ROTENONE; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AMINO ACID SEQUENCE; APOPTOSIS; CASPASE 3; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOCYTES; MALE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; ROTENONE; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73649098007     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00472.x     Document Type: Article

References (59)

1. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008 7 : 97 109.
2. Belin AC, Westerlund M. Parkinson's disease: a genetic perspective. FEBS J 2008 275 : 1377 1383.
3. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005 113 : 1230 1233.
4. Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 2008 8 : 6.
5. Bové J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005 2 : 484 894.
6. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007 100 : 1469 1479.
7. Lenaz G, Fato R, Genova ML, Bergamini C, Bianchi C, Biondi A. Mitochondrial Complex I: structural and functional aspects. Biochim Biophys Acta 2006 1757 : 1406 1420.
8. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003 23 : 10756 10764. (Pubitemid 37499681)
9. Watabe M, Nakaki T. ATP depletion does not account for apoptosis induced by inhibition of mitochondrial electron transport chain in human dopaminergic cells. Neuropharmacology 2007 52 : 536 541.
10. Kweon GR, Marks JD, Krencik R, Leung EH, Schumacker PT, Hyland K et al. Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. J Biol Chem 2004 279 : 51783 51792.
11. Moon Y, Lee KH, Park JH, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 2005 93 : 1199 1208.
12. Ahmadi FA, Linseman DA, Grammatopoulos TN, Jones SM, Bouchard RJ, Freed CR et al. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J Neurochem 2003 87 : 914 921.
13. Tada-Oikawa S, Hiraku Y, Kawanishi M, Kawanishi S. Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. Life Sci 2003 73 : 3277 3288.
14. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 2003 278 : 8516 8525.
15. Klintworth H, Newhouse K, Li T, Choi WS, Faigle R, Xia Z. Activation of c-Jun N-terminal protein kinase is a common mechanism underlying paraquat- and rotenone-induced dopaminergic cell apoptosis. Toxicol Sci 2007 97 : 149 162.
16. Ramachandiran S, Hansen JM, Jones DP, Richardson JR, Miller GW. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol Sci 2007 95 : 163 711.
17. Marella M, Boo-Seo B, Matsuno-Yagi A, Yagi T. Mechanism of cell death caused by complex I defects in a rat dopaminergic cell line. J Biol Chem 2007 282 : 24146 24156.
18. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994 63 : 1987 1990.
19. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 2006 17 : 305 323.
20. 2)-induced apoptosis in lymphocytes by reciprocal NF-κB activation and p53 inhibition via PI3K-dependent pathway. Growth Factors 2006 24 : 67 78.
21. Kurmasheva RT, Houghton PJ. IGF-1 mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006 1766 : 1 22.
22. O'Neill MJ, Messenger MJ, Lakics V, Murray TK, Karran EH, Szekeres PG et al. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. Int Rev Neurobiol 2007 77 : 179 217.
23. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, Wang CY et al. Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 2007 177 : 253 264.
24. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S, Frigo G. Endogenous catecholamine synthesis, metabolism, storage, and uptake in human peripheral blood mononuclear cells. Exp Hematol 1999 27 : 489 495. (Pubitemid 29125057)
25. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A et al. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 2001 117 : 133 142.
26. Ricci A, Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 1994 53 : 1 7.
27. Ricci A, Veglio F, Amenta F. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H] 7-OH-DPAT. J Neuroimmunol 1995 58 : 139 144.
28. Ricci A, Bronzetti E, Felici L, Tayebati SK, Amenta F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 1997 229 : 130 134.
29. Amenta F, Bronzetti E, Felici L, Ricci A, Tayebati SK. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 1999 19 : 151 159. (Pubitemid 29443882)
30. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002 132 : 34 40.
31. Kerr JFR, Gobe GC, Winterford CM, Harmon BV. Anatomical methods in cell death. In : Schwartz LM, Osborne BA (eds). Methods in Cell Death. Academic Press, London, 1995 1 27.
32. Kalinichenko SG, Matveeva NY. Morphological characteristics of apoptosis and its significance in neurogenesis. Neurosci Behav Physiol 2008 38 : 333 344.
33. Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, Berman JS. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest 1988 82 : 950 957.
34. Kooijman R, Willems M, Rijkers GT, Brinkman A, van Buul-Offers SC, Heijnen CJ et al. Effects of insulin-like growth factors and growth hormone on the in vitro proliferation of T lymphocytes. J Neuroimmunol 1992 38 : 95 104.
35. Melinn M, McLaughlin H. Nitroblue tetrazolium reduction in lymphocytes. J Leukoc Biol 1987 41 : 325 329.
36. Rothe G, Valet G. Flow cytometric assays of oxidative burst activity phagocytes. Methods Enzymol 1994 233 : 539 548.
37. Radad K, Rausch WD, Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 2006 49 : 379 386.
38. Radad K, Gille G, Rausch WD. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol In Vitro 2008 22 : 68 74.
39. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005 134 : 109 118.
40. Wang X, Perez E, Liu R, Yan LJ, Mallet RT, Yang SH. Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells. Brain Res 2007 1132 : 1 9.
41. Jagtap JC, Chandele A, Chopde BA, Shastry P. Sodium pyruvate protects against H(2)O(2) mediated apoptosis in human neuroblastoma cell line-SK-N-MC. J Chem Neuroanat 2003 26 : 109 118.
42. Jimenez-Del-Rio M, Velez-Pardo C. Paraquat induces apoptosis in human lymphocytes: protective and rescue effects of glucose, cannabinoids and insulin-growth factor-1. Growth Factors 2008 26 : 49 60.
43. 2), caspase-3, and nuclear factor kappa-B (NF-κB), p53, c-Jun transcription factor. Biochem Pharmacol 2002 63 : 677 688.
44. 2), caspase-3, NF-kappa B, p53 and c-Jun. NeuroToxicology 2002 23 : 351 365.
45. Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, Wang Y et al. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res 2007 1145 : 190 203.
46. Li LY, Zhao XL, Fei XF, Gu ZL, Qin ZH, Liang ZQ. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra. Acta Pharmacol Sin 2008 29 : 539 547.
47. Aleyasin H, Cregan SP, Iyirhiaro G, O'Hare MJ, Callaghan SM, Slack RS et al. Nuclear factor-(kappa) B modulates the p53 response in neurons exposed to DNA damage. J Neurosci 2004 24 : 2963 2973.
48. Ebadi M, Sharma SK, Wanpen S, Amornpan A. Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med 2004 8 : 213 222.
49. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007 414 : 94 7.
50. Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 2008 39 : 2129 2137.
51. Wang X, Qin ZH, Shi H, Savitz SI, Qin AP, Jiang Y et al. Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF- kappaB signaling pathway in a rat model of permanent focal cerebral ischemia. Brain Res 2008 1234 : 8 15.
52. Pande V, Ramos MJ. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 2005 12 : 357 374.
53. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 2006 13 : 730 737.
54. Hu MC, Qiu WR, Wang YP. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 1997 15 : 2277 2287.
55. Oleinik NV, Krupenko NI, Krupenko SA. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene 2007 26 : 7222 7230.
56. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007 87 : 99 163. (Pubitemid 46209992)
57. Puche JE, García-Fernández M, Muntané J, Rioja J, González-Barón S, Castilla Cortazar I. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008 149 : 2620 2627.
58. Baregamian N, Song J, Jeschke MG, Evers BM, Chung DH. IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis. J Surg Res 2006 136 : 31 7.
59. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett 2001 316 : 129 132.